" Applications of CRISPR technology for gene editing have revolutionized modern molecular biology. The ability to modify DNA in living organisms with precision down to a single position in the genetic code has never been possible with the speed and simplicity offered by CRISPR. This has enabled new discoveries into the functions of specific genes and regulatory sequences in a wide variety of species across the tree of life. These discoveries in turn fuel development of new therapeutics, can be used to cure inherited genetic diseases, spur creation of new crop varieties, along with myriad other unforeseen innovations. One rapidly advancing area of genetic and therapeutic research is the endocannabinoid system, which was only first discovered in 1992 with the identification of the first human endocannabinoid, anandamide. The interaction between endocannabinoids (signaling molecules) and their receptors found throughout the human body has only just begun to be elucidated, yet this system has been implicated in an incredibly vast range of diseases including Cron’s, Parkinsons, diabetes, fibromyalgia, multiple sclerosis and many more."

 

-- Elijah Spinah, Delta Leaf Laboratories. We are advancing the development of cannabinoid therapeutics through the application of CRISPR technology to dissect the function of phytocannabinoid genes and design modified versions of phytocannabinoid genes that may be used to improve human health.